Joseph Schwartz
Stock Analyst at Leerink Partners
(1.35)
# 3,384
Out of 4,761 analysts
142
Total ratings
32.52%
Success rate
-1.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $21.98 | +81.98% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.53 | +2,541.51% | 2 | Sep 19, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Market Perform | $4 | $3.85 | +3.90% | 3 | Sep 12, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.13 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $5.78 | +107.61% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $2.85 | +180.70% | 2 | Jun 20, 2024 | |
| RGLS Regulus Therapeutics | Initiates: Outperform | $6 | $1.31 | +358.02% | 2 | Mar 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | $9 → $2 | $0.42 | +376.19% | 5 | Mar 14, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.36 | -26.47% | 4 | Feb 9, 2024 | |
| DSGN Design Therapeutics | Downgrades: Market Perform | $6 | $4.91 | +22.20% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $50.69 | -5.31% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $16.49 | +9.16% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $10.03 | +99.40% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $32.32 | +5.20% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $68.25 | +90.48% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $106.28 | +50.55% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $152.43 | +6.93% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.40 | +614.29% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.37 | +2,308.76% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $7.93 | +51.32% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $42.59 | +153.58% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $50 | $81.06 | -38.32% | 3 | Oct 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $37.46 | +4.11% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.83 | +118.58% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $27.07 | +10.82% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $31.12 | +60.67% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $38.75 | -22.58% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $12.84 | +336.14% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.19 | +52.34% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.56 | +368.75% | 2 | Sep 26, 2017 |
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $21.98
Upside: +81.98%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.53
Upside: +2,541.51%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Market Perform
Price Target: $4
Current: $3.85
Upside: +3.90%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.13
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.78
Upside: +107.61%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.85
Upside: +180.70%
Regulus Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: $6
Current: $1.31
Upside: +358.02%
Spruce Biosciences
Mar 14, 2024
Downgrades: Market Perform
Price Target: $9 → $2
Current: $0.42
Upside: +376.19%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.36
Upside: -26.47%
Design Therapeutics
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $4.91
Upside: +22.20%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $50.69
Upside: -5.31%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $16.49
Upside: +9.16%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $10.03
Upside: +99.40%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $32.32
Upside: +5.20%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $68.25
Upside: +90.48%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $106.28
Upside: +50.55%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $152.43
Upside: +6.93%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.40
Upside: +614.29%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.37
Upside: +2,308.76%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $7.93
Upside: +51.32%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $42.59
Upside: +153.58%
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $81.06
Upside: -38.32%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $37.46
Upside: +4.11%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.83
Upside: +118.58%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $27.07
Upside: +10.82%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $31.12
Upside: +60.67%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $38.75
Upside: -22.58%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $12.84
Upside: +336.14%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $9.19
Upside: +52.34%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.56
Upside: +368.75%